Arimidex, Tamoxifen, and Adverse Events

Results of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial indicated that arimidex was associated with significantly less predefined gynecologic adverse events (AEs) than tamoxifen (including vaginal bleeding and discharge and endometrial cancer) in postmenopausal women with localized early breast cancer who were followed for a median of 5.6 years. To further compare AEs of these drugs, researchers from St. James’s University Hospital, Leeds; Christie Hospital NHS Trust, Manchester; Wolfson Institute of Preventive Medicine, London; and University College London, London, all in Great Britain, and Universitätsklinikum, Dresden, Germany retrospectively compared the incidence of gynecologic AEs not predetermined in the ATAC trial, as well as the number of gynecologic interventions performed.